DURUSU TANRIÖVER, M. Et Al. 2022. Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. VACCINES , vol.10, no.11 .

DURUSU TANRIÖVER, M., Aydin, O. A., Guner, R., YILDIZ, O., Celik, I., Doganay, H. L., ... Kose, S.(2022). Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. VACCINES , vol.10, no.11.

DURUSU TANRIÖVER, MİNE Et Al. "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial," VACCINES , vol.10, no.11, 2022

DURUSU TANRIÖVER, MİNE D. Et Al. "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial." VACCINES , vol.10, no.11, 2022

DURUSU TANRIÖVER, M. Et Al. (2022) . "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial." VACCINES , vol.10, no.11.

@article{article, author={MİNE DURUSU TANRIÖVER Et Al. }, title={Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial}, journal={VACCINES}, year=2022}